Abbvie (($ABBV)) announced an update on their ongoing clinical study. AbbVie recently updated its clinical study titled A ...

Merck's two-drug HIV regimen doravirine/islatravir maintained viral suppression and matched Gilead's Biktarvy in Phase 3 ...

Gilead has chosen a partner for lenacapavir in the race to develop new low-frequency treatments for HIV. | Gilead has chosen ...

More than 40 years have passed since the CDC reported the first cases of HIV in the United States. In that time, we’ve ...

HIV prevention drug Lenacapavir, which has been tested in South Africa during clinical trials, will be made available in the country in 2026 for high-risk groups.

The rate of HIV infection continues to climb globally. Around 40 million people live with HIV-1, the most common HIV strain.

Researchers used cryo-EM to study how the HIV enzyme integrase arranges in 3D to slip its DNA into the host genome and pack ...

Leaders in HIV research highlighted the critical role of that research has played in advancing HIV science over the past 40 years. In a commentary in Nature Medicine, they explained how U.S.-funded ...

Gilead Sciences said on Thursday its HIV drug sales rose 4% to $5.3 billion in the third quarter including $39 million for ...

Addressing the question of whether and how immune cells (macrophages) in the central nervous system (CNS) traffic out, ...

A University of Massachusetts Amherst public health researcher has received four grants totaling $17.9 million from the ...

WHO has sounded alarm over a sharp spike in HIV cases in the Philippines, Fiji and Papua New Guinea, urging urgent prevention ...